Three breast cancer cohorts demonstrated that patients with increased SPARCL1 have a better prognosis (GSE 9195, RFS HR = 0.31, Cox p = 0.003; GSE1456-GPL96, OS HR = 0.45, Cox p < 0.001; GSE12276, RFS HR = 0.73, Cox p = 0.004) (Figures 4C–E). The gene discussed is SPARCL1; the disease is breast carcinoma.